EGFR and glioblastoma: For example, using TCGA glioblastoma samples, Mueller and colleagues, have recently shown that the use of LCM is a necessary step to accurately correlate protein expression/activation with genomic alterations (e.g. PTEN loss or EGFR mutation) [21].